[go: up one dir, main page]

MX2010008197A - Nuevas piridinonas y piridazinonas. - Google Patents

Nuevas piridinonas y piridazinonas.

Info

Publication number
MX2010008197A
MX2010008197A MX2010008197A MX2010008197A MX2010008197A MX 2010008197 A MX2010008197 A MX 2010008197A MX 2010008197 A MX2010008197 A MX 2010008197A MX 2010008197 A MX2010008197 A MX 2010008197A MX 2010008197 A MX2010008197 A MX 2010008197A
Authority
MX
Mexico
Prior art keywords
btk
compounds
phenyl
iii
pyridazinones
Prior art date
Application number
MX2010008197A
Other languages
English (en)
Inventor
Nolan James Dewdney
Zachary Kevin Sweeney
Michael Soth
Timothy D Owens
Joshua Kennedy-Smith
Rama K Kondru
Bradley E Loe
Yan Lou
Joel Mcintosh
Joshua Paul Gergely Taygerly
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2010008197A publication Critical patent/MX2010008197A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Esta solicitud se refiere a derivados de 5-fenil-1H-piridin-2-ona y 6-fenil-2H-piridazin-3-ona de las fórmulas genéricas I-III: (ver formulas) en las que las variables R, X, Y1, Y2, Y3, Y4, n y m tienen los significados definidos anteriormente, que inhiben la Btk. Los elementos aquí descritos son útiles para modular la actividad de la Btk y tratar enfermedades asociadas con una actividad excesiva de la Btk. Además, estos compuestos son útiles para tratar enfermedades inflamatorias y autoinmunitarios asociadas con la proliferación aberrante de células B, por ejemplo la artritis reumatoide. Se describen también composiciones que contienen los compuestos de las fórmulas I-III y por lo menos un vehículo, diluyente o excipiente.
MX2010008197A 2008-02-05 2009-01-27 Nuevas piridinonas y piridazinonas. MX2010008197A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2620408P 2008-02-05 2008-02-05
US12251008P 2008-12-15 2008-12-15
PCT/EP2009/050875 WO2009098144A1 (en) 2008-02-05 2009-01-27 Novel pyridinones and pyridazinones

Publications (1)

Publication Number Publication Date
MX2010008197A true MX2010008197A (es) 2010-08-23

Family

ID=40413736

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010008197A MX2010008197A (es) 2008-02-05 2009-01-27 Nuevas piridinonas y piridazinonas.

Country Status (29)

Country Link
EP (1) EP2242749B1 (es)
JP (1) JP5259739B2 (es)
KR (1) KR101308803B1 (es)
CN (1) CN101932573B (es)
AR (1) AR070408A1 (es)
AU (1) AU2009211514B2 (es)
BR (1) BRPI0907915A2 (es)
CA (1) CA2710462C (es)
CL (1) CL2009000229A1 (es)
CO (1) CO6290767A2 (es)
CR (1) CR11598A (es)
CY (1) CY1114114T1 (es)
DK (1) DK2242749T3 (es)
EC (1) ECSP10010384A (es)
ES (1) ES2420846T3 (es)
HR (1) HRP20130615T1 (es)
IL (1) IL206357A (es)
MA (1) MA32064B1 (es)
MX (1) MX2010008197A (es)
MY (1) MY158411A (es)
NZ (1) NZ586916A (es)
PE (1) PE20091484A1 (es)
PL (1) PL2242749T3 (es)
PT (1) PT2242749E (es)
RU (1) RU2505538C2 (es)
SI (1) SI2242749T1 (es)
TW (1) TWI382024B (es)
WO (1) WO2009098144A1 (es)
ZA (1) ZA201005539B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2728016C (en) 2008-06-24 2017-02-28 F. Hoffmann-La Roche Ag Novel substituted pyridin-2-ones and pyridazin-3-ones
US8299077B2 (en) * 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
SG175287A1 (en) * 2009-04-24 2011-11-28 Hoffmann La Roche Inhibitors of bruton's tyrosine kinase
PL2473049T3 (pl) 2009-09-04 2019-07-31 Biogen Ma Inc. Inhibitory kinazy tyrozynowej brutona
CN110818724B (zh) * 2010-05-07 2020-11-13 吉利德康涅狄格有限公司 吡啶酮和氮杂吡啶酮化合物及使用方法
EP2394998A1 (en) * 2010-05-31 2011-12-14 Almirall, S.A. 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors
AR082590A1 (es) 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
ES2590491T3 (es) * 2011-05-17 2016-11-22 F. Hoffmann-La Roche Ag Inhibidores de la tirosina quinasa de Bruton
CA2841801A1 (en) * 2011-08-17 2013-02-21 F.Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
US9365566B2 (en) 2012-03-27 2016-06-14 Takeda Pharmaceutical Company Limited Cinnoline derivatives
BR112014024693A2 (pt) 2012-04-05 2017-07-11 Chdi Foundation Inc composto de fórmula / ou um sal farmaceuticamente aceitável ou pró-fármaco do mesmo; composto; composição farmacêutica; método de tratamento de uma afecção ou distúrbio mediado por atividade de quinurenina 3-mono-oxigenase em um indivíduo que necessita de tal tratamento
CN104662018B (zh) 2012-04-20 2017-10-24 阿迪维纳斯治疗有限公司 取代的杂双环化合物、组合物及其医疗应用
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
KR20150054994A (ko) * 2012-09-13 2015-05-20 에프. 호프만-라 로슈 아게 브루톤 티로신 키나아제의 억제제
WO2014076104A1 (en) * 2012-11-16 2014-05-22 F. Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
RU2015122218A (ru) * 2012-11-30 2017-01-10 Ф. Хоффманн-Ля Рош Аг Ингибиторы тирозинкиназы брутона
JP6089124B2 (ja) 2013-03-05 2017-03-01 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ブルトン型チロシンキナーゼの阻害薬
EP2964642B1 (en) * 2013-03-05 2017-11-15 F. Hoffmann-La Roche AG Inhibitors of bruton's tyrosine kinase
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
ES2619125T3 (es) 2013-04-25 2017-06-23 Beigene, Ltd. Compuestos heterocíclicos fusionados como inhibidores de proteína cinasa
CN104177338B (zh) * 2013-05-22 2018-04-03 南京勇山生物科技有限公司 一类布鲁顿激酶抑制剂
CA2912359A1 (en) * 2013-07-03 2015-01-08 F. Hoffmann-La Roche Ag Heteroaryl pyridone and aza-pyridone amide compounds
IL296026B2 (en) 2013-09-13 2024-10-01 Beigene Switzerland Gmbh Anti-pd1 antibodies and their use as therapeutics and diagnostics
KR101813830B1 (ko) * 2013-12-05 2017-12-29 에프. 호프만-라 로슈 아게 친전자성 작용기를 갖는 헤테로아릴 피리돈 및 아자-피리돈 화합물
JP6526189B2 (ja) 2014-07-03 2019-06-05 ベイジーン リミテッド 抗ｐｄ−ｌ１抗体並びにその治療及び診断のための使用
JP6507234B2 (ja) * 2014-10-02 2019-04-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ブルトンチロシンキナーゼ（ｂｔｋ）によって介入される障害の処置における使用のためのピラゾールカルボキサミド化合物
JP6916185B2 (ja) * 2016-01-13 2021-08-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｔｋ阻害剤としてのイソキノロン類
PL3436447T3 (pl) 2016-03-31 2021-12-27 Takeda Pharmaceutical Company Limited Kompleksy triazolonu izochinolinylowego
WO2018007885A1 (en) 2016-07-05 2018-01-11 Beigene, Ltd. COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER
WO2018017153A1 (en) 2016-07-21 2018-01-25 Biogen Ma Inc. Succinate forms and compositions of bruton's tyrosine kinase inhibitors
SG11201901141WA (en) 2016-08-16 2019-03-28 Beigene Ltd Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
PT3500299T (pt) 2016-08-19 2024-02-21 Beigene Switzerland Gmbh Combinação de zanubrutinib com um anticorpo anti-cd20 ou anti-pd-1 para utilização no tratamento do cancro
EP3515414B1 (en) 2016-09-19 2022-11-30 MEI Pharma, Inc. Combination therapy
CN110461847B (zh) 2017-01-25 2022-06-07 百济神州有限公司 (S)-7-(1-(丁-2-炔酰基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氢吡唑并[1,5-a]嘧啶-3-甲酰胺的结晶形式、其制备及用途
CN106967073A (zh) * 2017-04-24 2017-07-21 刘双伟 一种治疗类风湿性关节炎的药物
CN108164536A (zh) * 2017-05-08 2018-06-15 刘双伟 一种用于治疗类风湿性关节炎的新的化合物的合成方法
TWI877099B (zh) 2017-06-26 2025-03-21 英屬開曼群島商百濟神州有限公司 抗ｐｄ－１抗體或其抗原結合片段在製備治療用於患有肝細胞癌（ｈｃｃ）之藥物的用途
WO2019034009A1 (en) 2017-08-12 2019-02-21 Beigene, Ltd. BTK INHIBITOR WITH ENHANCED DOUBLE SELECTIVITY
WO2019108795A1 (en) 2017-11-29 2019-06-06 Beigene Switzerland Gmbh Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
BR112021007115A2 (pt) 2018-10-15 2021-07-20 Nurix Therapeutics, Inc. compostos bifuncionais para dedradação de btk por meio da via de proteossoma de ubiquitina
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
CN114364667B (zh) 2019-04-09 2025-01-10 紐力克斯治疗公司 用于Cbl-b抑制的3-取代哌啶类化合物以及Cbl-b抑制剂与癌症疫苗和/或溶瘤病毒联合的用途
CA3140873A1 (en) 2019-05-17 2020-11-26 Nurix Therapeutics, Inc. Cyano cyclobutyl compounds for cbl-b inhibition and uses thereof
TWI856111B (zh) 2019-06-10 2024-09-21 瑞士商百濟神州瑞士有限責任公司 一種含有布魯頓氏酪胺酸激酶抑制劑的口服固體錠劑及其製備方法
US11401267B2 (en) 2019-06-26 2022-08-02 Nurix Therapeutics, Inc. Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
US20230024442A1 (en) * 2019-11-08 2023-01-26 Nurix Therapeutics, Inc. Bifunctional compounds for grading btk via ubiquitin proteosome pathway
WO2021113557A1 (en) 2019-12-04 2021-06-10 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
JP2024514836A (ja) 2021-04-08 2024-04-03 ニューリックス セラピューティクス，インコーポレイテッド Ｃｂｌ－ｂ阻害化合物との組み合わせ療法
EP4422630A1 (en) 2021-10-26 2024-09-04 Nurix Therapeutics, Inc. Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk
US11786531B1 (en) 2022-06-08 2023-10-17 Beigene Switzerland Gmbh Methods of treating B-cell proliferative disorder

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3951395B2 (ja) * 1996-12-13 2007-08-01 田辺製薬株式会社 ピリジン誘導体、その製法及びその合成中間体
RU2242474C2 (ru) * 1999-03-12 2004-12-20 Бёрингер Ингельхайм Фармасьютиклз, Инк. Соединения, пригодные в качестве противовоспалительных агентов
ES2232306B1 (es) * 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
KR20070095952A (ko) * 2004-12-16 2007-10-01 버텍스 파마슈티칼스 인코포레이티드 염증성 질환, 증식성 질환 및 면역학적으로 매개된 질환치료용 Ｔｅｃ 계열 단백질 키나제의 억제제로서 유용한피리드-2-온
MY140868A (en) * 2004-12-24 2010-01-29 Astrazeneca Ab Amide derivatives
AU2006223409B2 (en) * 2005-03-10 2011-07-21 Gilead Connecticut, Inc. Certain substituted amides, method of making, and method of use thereof
WO2006124731A2 (en) * 2005-05-12 2006-11-23 Irm Llc Compounds and compositions as protein kinase inhibitors
BRPI0614804A2 (pt) * 2005-08-09 2011-04-12 Irm Llc compostos e composições como inibidores de proteìna cinase
CA2620269A1 (en) 2005-08-29 2007-03-08 Vertex Pharmaceuticals Incorporated 3,5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases
KR20080109095A (ko) * 2006-05-15 2008-12-16 아이알엠 엘엘씨 Ｆｇｆ 수용체 키나제 억제제를 위한 조성물 및 방법

Also Published As

Publication number Publication date
CY1114114T1 (el) 2016-07-27
SI2242749T1 (sl) 2013-07-31
PE20091484A1 (es) 2009-10-03
HRP20130615T1 (en) 2013-08-31
RU2505538C2 (ru) 2014-01-27
JP5259739B2 (ja) 2013-08-07
KR101308803B1 (ko) 2013-09-13
MA32064B1 (fr) 2011-02-01
TW200938538A (en) 2009-09-16
CO6290767A2 (es) 2011-06-20
IL206357A (en) 2013-12-31
WO2009098144A1 (en) 2009-08-13
PL2242749T3 (pl) 2013-09-30
JP2011511027A (ja) 2011-04-07
ES2420846T3 (es) 2013-08-27
TWI382024B (zh) 2013-01-11
CR11598A (es) 2010-10-27
ZA201005539B (en) 2011-04-28
CN101932573A (zh) 2010-12-29
AU2009211514B2 (en) 2014-02-20
BRPI0907915A2 (pt) 2015-07-28
AU2009211514A1 (en) 2009-08-13
CA2710462C (en) 2015-11-24
MY158411A (en) 2016-10-14
KR20100093130A (ko) 2010-08-24
RU2010136665A (ru) 2012-03-20
EP2242749A1 (en) 2010-10-27
NZ586916A (en) 2012-06-29
CL2009000229A1 (es) 2010-06-04
DK2242749T3 (da) 2013-06-17
ECSP10010384A (es) 2010-09-30
HK1146826A1 (en) 2011-07-15
IL206357A0 (en) 2010-12-30
CN101932573B (zh) 2014-06-11
PT2242749E (pt) 2013-07-16
EP2242749B1 (en) 2013-04-10
CA2710462A1 (en) 2009-08-13
AR070408A1 (es) 2010-04-07

Similar Documents

Publication Publication Date Title
MX2010008197A (es) Nuevas piridinonas y piridazinonas.
PH12012502374A1 (en) Novel substituted pyridin-2-ones and pyridazin-3-ones
PH12013502379A1 (en) Inhibitors of bruton's tyrosine kinase
PH12014500128A1 (en) Inhibitors of bruton's tyrosine kinase
MX339583B (es) Inhibidores de tirosina cinasa de bruton.
WO2014064131A3 (en) Inhibitors of bruton's tyrosine kinase
EA201390207A1 (ru) Ингибиторы тирозинкиназы брутона
JO2910B1 (en) Organic compounds
GEP20156285B (en) Compounds and compositions as trk inhibitors
TN2011000221A1 (en) Pyrazine compounds as phosphodiesterase 10 inhibitors
TN2011000220A1 (en) Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors
MX2008010671A (es) Derivados de cinolina como inhibidores de fosfodiesterasa 10.
MX2010009023A (es) Inhibidores de cinasas de pirrolopirazina.
NZ587215A (en) Tricyclic compounds having corticotropin-releasing factor antagonistic activity and pharmaceutical compositions containing them
MX2009011754A (es) Inhibidores de enzima de diacilglicerol o-aciltransferasa tipo 1.
EA201390015A1 (ru) Композиции и способы ингибирования пути jak
ZA201006782B (en) Novel p2x7r antagonists and thier use
TW200942535A (en) Novel compounds as cannabinoid receptor ligands
MX2010006166A (es) Compuestos amida como refuerzos de antivirales.
MX2009011753A (es) Inhibidores de enzima de diacilglicerol o-aciltransferasa tipo 1.
MX2008011175A (es) Inhibidores de fosfodiesterasa 10.
MX348024B (es) Compuestos de adamantilo.
MX2015007291A (es) Derivados de tiazol como inhibidores de la tirosina cinasa de bruton.
MX374758B (es) Inhibidores de tirosina cinasa de bruton.
DE502008002974D1 (de) ä Ä5- ( PHENYL) - 6- PHENYLPYRROLO Ä2,1-FÜÄ2,1, 4ÜTRIAZIN-4-YLÜAMINOü CARBONSÄUREDERIVATE UND VERWANDTE VERBINDUNGEN ALS PROSTAZYKLIN (PGI2) IP-REZEPTOR AKTIVATOREN ZUR BEHANDLUNG VON KARDIOVASKULÄREN ERKRANKUNGEN

Legal Events

Date Code Title Description
FG Grant or registration